Skip to main content
. 2018 Aug 22;12:66. doi: 10.3389/fncir.2018.00066

FIGURE 5.

FIGURE 5

The Vip-FlpO driver targeted 3 types of ACs. The Vip-FlpO driver was crossed with UBC-CreER2 and Ai65, 20 μg tamoxifen was administered to achieve sparse labeling of ACs. Representative images for VIP-1 AC (A), VIP-2 AC (B), and VIP-3 AC (C) are shown in flat-mount view (top) and side view (bottom) with ChAT (blue) in (i). Arrow in (Ai) shows the “tail” of the VIP-1 AC. Sections were co-labeled with antibodies against GABA (green) (ii) and VIP (green) (iii). Scale bar: 25 μm for flat-mount view, 10 μm for side view.